Similarly, Finlin et al. demonstrated that a cohort of older individuals with obesity and insulin resistance treated with mirabegron (50 mg/day for 12 weeks) displayed amelioration of multiple measures of glucose metabolism (i.e. reduced HbA1c levels, increased insulin sensitivity, improved β-cell function) without a significant body weight loss [83]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.